German OncoLogical Data Standard (GOLD)
========================

.. start-badges

.. image:: https://github.com/vision-zero-oncology/GOLD/actions/workflows/fhir-validate.yml/badge.svg
    :target: https://github.com/vision-zero-oncology/GOLD/actions/workflows/fhir-validate.yml
    :alt: FSH/FHIR Validation

.. image:: https://github.com/vision-zero-oncology/GOLD/actions/workflows/ig-publish.yml/badge.svg
    :target: https://github.com/vision-zero-oncology/GOLD/actions/workflows/ig-publish.yml
    :alt: IG Publisher

Summary
-------
Implementation guide for the German OncoLogical Data Standard (GOLD).

Publication
-----------
This Implementation Guide is published in the following locations:

* Current Build: https://vision-zero-oncology.github.io/GOLD/

Issues
------
Please feel free to contribute to this implementation guide. Issues and change requests are managed here:

* Issues: https://github.com/vision-zero-oncology/GOLD/issues

------

GOLD Implementation Group
------

Working Group Christof von Kalle, CSC Charité & BIH (in alphabetical order)

* `Liudmila Lysyakova <https://github.com/mila-lysyakova>`_
* Stefanie Rudolph

Working Group Sylvia Thun, BIH@Charité (in alphabetical order)

* `Andrea Essenwanger <https://github.com/bytegnome>`_
* `Julian Saß <https://github.com/julsas>`_
* Anna Trelinska-Finger, Charité CCC

Further Working Groups (in alphabetical order)

* Marc Bachmann, Novartis Pharma GmbH
* Katja Beck, MASTER Program NCT Heidelberg
* Loren Dimitrov, mint Medical GmbH
* `Johannes Kast <https://github.com/johannes-kast-mint>`_, mint Medical GmbH
* Simon Kreutzfeldt, MASTER Program NCT Heidelberg
* Thomas Massier, mint Medical GmbH
* Erika Schirghuber, Roche Pharma AG
* Christoph Benedikt Westphalen, CCC München LMU
* Niko Wolf, Snke OS GmbH Healthcare Plattform

Members of the Evaluation Group (in alphabetical order)
--------
* Lars Bullinger, Charité Universitätsmedizin Berlin
* Melanie Börries, Universitätsklinikum Freiburg
* Thomas Ganslandt, Friedrich-Alexander-Universität Erlangen-Nürnberg
* Alexander Kerscher, Onkologisches Zentrum Universitätsklinikum Würzburg, CCC MF Krebsregister
* Claus R. Lattrich, Roche Pharma AG
* Patrick Metzger, Universitätsklinikum Freiburg
* Mathias Muth, Novartis Pharma GmbH
* Stefan Palm, WTZ Essen, Westdeutsches Tumorzentrum Netzwerk
* Bärbel Söhlke, zielGENau e.V., Patientenvertreterin

